Outcomes of paclitaxel‐coated balloon angioplasty for in‐stent calcified nodule: An optical coherence tomography study

Background Paclitaxel‐coated balloon (PCB) angioplasty emerges as an effective therapeutic option for in‐stent restenosis (ISR). However, whether PCB angioplasty would be effective for in‐stent calcified nodule (ISCN) lesions remain fully understood. This study aimed to evaluate the frequency and ou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Catheterization and cardiovascular interventions 2022-11, Vol.100 (6), p.990-999
Hauptverfasser: Masuda, Hisaki, Kuramitsu, Shoichi, Ito, Tomoaki, Morofuji, Toru, Domei, Takenori, Hyodo, Makoto, Shirai, Shinichi, Ando, Kenji
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Paclitaxel‐coated balloon (PCB) angioplasty emerges as an effective therapeutic option for in‐stent restenosis (ISR). However, whether PCB angioplasty would be effective for in‐stent calcified nodule (ISCN) lesions remain fully understood. This study aimed to evaluate the frequency and outcomes of ISCN in patients undergoing PCB angioplasty for ISR after second‐generation drug‐eluting stents (G2‐DES) implantation. Methods This study enrolled 179 lesions (160 patients) undergoing PCB angioplasty for G2‐DES restenosis with optical coherence tomography guidance. According to the presence of ISCN at the minimum lumen area, the lesions were divided into two groups: the ISCN (n = 16) and the non‐ISCN groups (n = 163). The primary study endpoint was the cumulative 3‐year incidence of target lesion failure (TLF; a composite of cardiac death, clinically driven target vessel revascularization, and definite stent thrombosis) on a lesion basis. Results ISCN was observed in 16 of 179 lesions (8.9%). Cumulative 3‐year incidence of TLF was significantly higher in the ISCN group than in the non‐CN group (85.3% vs. 16.9%, inverse probability weighted hazard ratio [HR] 4.46, 95% confidence intervals [CIs]: 2.42–8.22, p 
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.30418